Description: Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the transactional research and medipolis businesses in Japan and internationally. It offers non-clinical studies, including single/repeated dose toxicity studies, antigenicity studies, skin sensitization studies, genotoxicity studies, carcinogenicity studies, local irritation studies, inhalation toxicity studies, TK studies, characteristic studies, stability studies, dependence studies, reproductive and developmental toxicity studies, safety pharmacological studies, and pharmacokinetic studies. The company also engages in the investigator brochure preparation support, clinical trial protocol creation support, clinical trial medical institution, investigational drug allocation, clinical trial request/contract, monitoring, quality management, data management, statistical analysis work, comprehensive report creation support, electronic application support, regulatory affairs consulting, and creating informed consent documents support services. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of vaccines and therapeutic drugs, antibody drugs, nucleic acid drugs, peptide drugs, gene therapy, and regenerative medicines. Further, the company is involved in the operates geothermal power generation; operates hotel accommodation facilities; and wellbeing businesses, as well as provides cleaning, clerical work, and welfare services. Shin Nippon Biomedical Laboratories, Ltd. was founded in 1957 and is headquartered in Kagoshima, Japan.
Home Page: www.snbl.co.jp
2438 Miyanoura-cho
Kagoshima,
891-1394
Japan
Phone:
81 9 9294 3389
Officers
| Name | Title |
|---|---|
| Dr. Ryoichi Nagata F.F.P.M., M.D., Ph.D. | President, Chairman, CEO, Group CFO, Fisheries Business Officer & Chief Health Officer |
| Fumihiko Makino | Senior Executive Officer, Financial Controller and GM of Finance & Accounting |
| Toshiyuki Iwata | Managing Executive Officer, R/PR Division Manager & Sustainability Officer |
| Shinji Nitanda | Senior MD of Corporate Development & Corporate Tax Administration and Director |
| Kyomi Nagatoshi | Senior Managing Executive Officer, Head of General Affairs & Human Resources and Director |
| Mr. Ken Takanashi CPA, MBA. | Executive VP of Group Corporate Management & Global Business & Director |
| Satoshi Matsumoto | Managing Executive Officer & GM of Fisheries Division |
| Dr. Hideshi Tsusaki DVM Ph.D. | Senior MD, President of Non-Clinical & Global Business Development and Director |
| Terumasa Hirai | Managing Executive Officer & President and Representative Director of SNBL Ina Research Center |
| Dr. Shu-Ichi Kanazashi M.D., Ph.D. | Managing Executive Officer, CMO and General Manager of TR Business Division |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 18.4457 |
| Price-to-Book MRQ: | 3.8087 |
| Price-to-Sales TTM: | 0.0261 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 1451 |